Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
Jun‐Te Hsu(Memorial Hospital of South Bend), Ta‐Sen Yeh(Chang Gung Memorial Hospital), Puo‐Hsien Le(Chang Gung University), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Huang‐Ping Yu(Chang Gung University), Chun‐Nan Yeh(Chang Gung University), Tsung‐Hsing Chen(Chang Gung University), Chia‐Jung Kuo(Chang Gung University), Yi-Yin Jan(Chang Gung Memorial Hospital), Chun‐Jung Lin(Chang Gung University), Chang‐Fu Kuo(Chang Gung University), Meng‐Jiun Chiou(China Medical University)
Cited by 10
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Intraductal papillary neoplasia of the liver associated with hepatolithiasis
|Hepatology|2001|282